Acyclovir Dosage in Chickenpox
For immunocompetent children with chickenpox, administer oral acyclovir 20 mg/kg per dose (maximum 800 mg) four times daily for 5 days, initiated within 24 hours of rash onset for optimal benefit. 1, 2, 3
Standard Dosing for Immunocompetent Children
- Oral acyclovir: 20 mg/kg per dose (maximum 800 mg/dose) four times daily for 5 days 1, 2, 3
- Children weighing >40 kg should receive the adult dose of 800 mg four times daily 3
- Treatment must begin within 24 hours of rash onset to achieve meaningful clinical benefit—this timing is critical for reducing lesion count, accelerating healing, and shortening fever duration to 3-4 days 2, 4
- When initiated within the first 24 hours, >95% of patients have no new lesions after day 3 2
Dosing for Immunocompromised Children
Severely immunocompromised children (CDC immunologic category 3) require intravenous acyclovir, not oral therapy. 1
- IV acyclovir: 10 mg/kg per dose every 8 hours (three times daily) for 7-10 days 1
- Alternative body surface area dosing: 500 mg/m² per dose IV every 8 hours for children >1 year old 1
- Children with mild to moderate immunosuppression (CDC categories 1-2) may use the standard oral regimen of 20 mg/kg four times daily 1
- Close physician observation is mandatory for all immunocompromised children receiving oral acyclovir, with readiness to switch to IV therapy if dissemination occurs 5
Renal Impairment Adjustments
Dose reduction is essential in renal impairment to prevent neurotoxicity. 3
For the 800 mg every 4 hours regimen (chickenpox dose):
- Creatinine clearance >25 mL/min/1.73m²: 800 mg every 4 hours (standard dosing) 3
- Creatinine clearance 10-25 mL/min/1.73m²: 800 mg every 8 hours 3
- Creatinine clearance 0-10 mL/min/1.73m²: 800 mg every 12 hours 3
Special renal considerations:
- Hemodialysis patients: Administer an additional dose after each dialysis session due to 60% reduction in plasma concentrations during 6-hour dialysis 3
- Peritoneal dialysis: No supplemental dose needed after interval adjustment 3
- End-stage renal failure: Loading dose 400 mg, then maintenance 200 mg twice daily 6
- Adequate hydration must be maintained to prevent acyclovir crystallization in renal tubules 3, 7
Critical Timing and Efficacy Considerations
- Efficacy is time-dependent: No data support treatment initiated >24 hours after rash onset 3, 4
- Treatment within 24 hours reduces mean lesion count from 347 (placebo) to 294 (acyclovir), with fewer patients developing >500 lesions (21% vs 38%) 4
- Acyclovir does not reduce person-to-person transmission or shorten school absence duration—it should not be used as a public health measure 2
- Treatment does not impair development of varicella-zoster virus antibodies, preserving long-term immunity 2
Common Pitfalls and Monitoring
- Neurotoxicity risk: Can occur even with reduced doses in renal failure; presents as reversible CNS symptoms 3, 6, 8
- Acute tubulointerstitial nephritis: Reported in children with nephrotic syndrome receiving IV acyclovir; monitor renal function closely 7
- High-dose regimens (15 mg/kg every 8 hours IV) used for VZV encephalitis carry increased acute renal failure risk 8
- Avoid concurrent nephrotoxic agents when possible 3
- Augmented renal clearance (eGFR >250 mL/min/1.73m²): May require higher IV doses of 15-20 mg/kg every 6 hours to achieve therapeutic concentrations 9
Who Should Receive Treatment
The American Academy of Pediatrics does not recommend routine acyclovir for all healthy children, as chickenpox is typically mild and self-limited. 10, 2
Consider treatment for: